{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:02:43Z","timestamp":1761512563061},"reference-count":34,"publisher":"American Diabetes Association","issue":"10","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,10,1]]},"abstract":"<jats:p>OBJECTIVES\u2014We sought to 1) Determine whether soluble-misfolded amylin or insoluble-fibrillar amylin may cause or result from diabetes in human amylin transgenic mice and 2) determine the role, if any, that insulin resistance might play in these processes.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014We characterized the phenotypes of independent transgenic mouse lines that display pancreas-specific expression of human amylin or a nonaggregating homolog, [25,28,29Pro]human amylin, in an FVB\/n background.<\/jats:p>\n               <jats:p>RESULTS\u2014Diabetes occurred in hemizygous human amylin transgenic mice from 6 weeks after birth. Glucose tolerance was impaired during the mid- and end-diabetic phases, in which progressive \u03b2-cell loss paralleled decreasing pancreatic and plasma insulin and amylin. Peripheral insulin resistance was absent because glucose uptake rates were equivalent in isolated soleus muscles from transgenic and control animals. Even in advanced diabetes, islets lacked amyloid deposits. In islets from nontransgenic mice, glucagon and somatostatin cells were present mainly at the periphery and insulin cells were mainly in the core; in contrast, all three cell types were distributed throughout the islet in transgenic animals. [25,28,29Pro]human amylin transgenic mice developed neither \u03b2-cell degeneration nor glucose intolerance.<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014Overexpression of fibrillogenic human amylin in these human amylin transgenic mice caused \u03b2-cell degeneration and diabetes through mechanisms independent from both peripheral insulin resistance and islet amyloid. These findings are consistent with \u03b2-cell death evoked by misfolded but soluble cytotoxic species, such as those formed by human amylin in vitro.<\/jats:p>","DOI":"10.2337\/db06-1755","type":"journal-article","created":{"date-parts":[[2008,7,16]],"date-time":"2008-07-16T04:18:47Z","timestamp":1216181927000},"page":"2737-2744","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":27,"title":["Spontaneous Diabetes in Hemizygous Human Amylin Transgenic Mice That Developed Neither Islet Amyloid nor Peripheral Insulin Resistance"],"prefix":"10.2337","volume":"57","author":[{"given":"Winifred P.S.","family":"Wong","sequence":"first","affiliation":[{"name":"School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Lin","family":"Chuang","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoping","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand"},{"name":"Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athena","family":"Ferreira","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etuate L.","family":"Saafi","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee Soon","family":"Choong","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garth J.S.","family":"Cooper","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand"},{"name":"Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand"},{"name":"MRC Immunochemistry Unit, Department of Biochemistry, University of Oxford, Oxford, U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031208093648400_R1","doi-asserted-by":"crossref","unstructured":"Maclean N, Ogilvie RF: Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes\u20084: 367\u2013376, 1955","DOI":"10.2337\/diab.4.5.367"},{"key":"2022031208093648400_R2","doi-asserted-by":"crossref","unstructured":"Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: \u03b2-Cell deficit and increased \u03b2-cell apoptosis in humans with type 2 diabetes. Diabetes\u200852: 102\u2013110, 2003","DOI":"10.2337\/diabetes.52.1.102"},{"key":"2022031208093648400_R3","doi-asserted-by":"crossref","unstructured":"Deng S, Vatamaniuk M, Huang X, Doliba N, Lian MM, Frank A, Velidedeoglu E, Desai NM, Koeberlein B, Wolf B, Barker CF, Naji A, Matschinsky FM, Markmann JF: Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes\u200853: 624\u2013632, 2004","DOI":"10.2337\/diabetes.53.3.624"},{"key":"2022031208093648400_R4","doi-asserted-by":"crossref","unstructured":"Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM: Purification and characterisation of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A\u200884: 8628\u20138632, 1987","DOI":"10.1073\/pnas.84.23.8628"},{"key":"2022031208093648400_R5","doi-asserted-by":"crossref","unstructured":"Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A\u200884: 3881\u20133885, 1987","DOI":"10.1073\/pnas.84.11.3881"},{"key":"2022031208093648400_R6","doi-asserted-by":"crossref","unstructured":"Glenner GG, Eanes DE, Wiley CA: Amyloid fibrils formed from a segment of the pancreatic islet amyloid protein. Biochem Biophys Res Commun\u2008155: 608\u2013614, 1988","DOI":"10.1016\/S0006-291X(88)80538-2"},{"key":"2022031208093648400_R7","doi-asserted-by":"crossref","unstructured":"Bell ET: Hyalinization of the islet of Langerhans in diabetes mellitus. Diabetes\u20081: 341\u2013344, 1952","DOI":"10.2337\/diab.1.5.341"},{"key":"2022031208093648400_R8","unstructured":"Bell ET: Hyalinization of the islets of Langerhans in non-diabetic individuals. Am J Pathol\u200835: 801\u2013805, 1959"},{"key":"2022031208093648400_R9","doi-asserted-by":"crossref","unstructured":"Clark A, Cooper GJS, Lewis CE, Willis AC, Morris JF, Reid KBM, Turner RC: Islet amyloid formed from diabetes-associated peptide may be pathogenic in type 2 diabetes. Lancet\u2008330: 231\u2013234, 1987","DOI":"10.1016\/S0140-6736(87)90825-7"},{"key":"2022031208093648400_R10","doi-asserted-by":"crossref","unstructured":"Westermark P, Grimelius L: The pancreatic islet cells in insular amyloidosis in human diabetic and non-diabetic adults. Acta Pathol Micro Scand A\u200881: 291\u2013300, 1973","DOI":"10.1111\/j.1699-0463.1973.tb03538.x"},{"key":"2022031208093648400_R11","doi-asserted-by":"crossref","unstructured":"Zhao HL, Lai FM, Tong PC, Zhong DR, Yang D, Tomlinson B, Chan JC: Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes. Diabetes\u200852: 2759\u20132766, 2003","DOI":"10.2337\/diabetes.52.11.2759"},{"key":"2022031208093648400_R12","doi-asserted-by":"crossref","unstructured":"Howard CF Jr: Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia\u200829: 301\u2013306, 1986","DOI":"10.1007\/BF00452067"},{"key":"2022031208093648400_R13","unstructured":"Johnson KH, O'Brien TD, Jordan K, Westermark P: Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells. Am J Pathol\u2008135: 245\u2013250, 1989"},{"key":"2022031208093648400_R14","doi-asserted-by":"crossref","unstructured":"Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature\u2008368: 756\u2013760, 1994","DOI":"10.1038\/368756a0"},{"key":"2022031208093648400_R15","doi-asserted-by":"crossref","unstructured":"Saafi EL, Konarkowska B, Zhang S, Kistler J, Cooper GJS: Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in RINm5F pancreatic islet \u03b2-cells. Cell Biol Int\u200825: 339\u2013350, 2001","DOI":"10.1006\/cbir.2000.0643"},{"key":"2022031208093648400_R16","doi-asserted-by":"crossref","unstructured":"D'Alessio DA, Verchere CB, Kahn SE, Hoagland V, Baskin DG, Palmiter RD, Ensinck JW: Pancreatic expression and secretion of human islet amyloid polypeptide in transgenic mice. Diabetes\u200843: 1457\u20131461, 1994","DOI":"10.2337\/diabetes.43.12.1457"},{"key":"2022031208093648400_R17","doi-asserted-by":"crossref","unstructured":"Fox N, Schrementi J, Nishi M, Ohagi S, Chan SJ, Heisserman JA, Westermark GT, Leckstrom A, Westermark P, Steiner DF: Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS Lett\u2008323: 40\u201344, 1993","DOI":"10.1016\/0014-5793(93)81444-5"},{"key":"2022031208093648400_R18","doi-asserted-by":"crossref","unstructured":"Hoppener JWM, Verbeek JS, de Koning EJP, Oosterwijk C, van Hulst KL, Visser- Vernooy HJ, Hofhuis E, van Gaalen S, Berends MJH, Hackeng WHL, Jansz HS, Morris JF, Clark A, Capel PJA, Lips CJM: Chronic overproduction of islet amyloid polypeptide\/amylin in transgenic mice: lysosomal localisation of human islet amyloid polypeptide and lack of marked hyperglycemia or hyperinsulinaemia. Diabetologia\u200836: 1258\u20131265, 1993","DOI":"10.1007\/BF00400803"},{"key":"2022031208093648400_R19","doi-asserted-by":"crossref","unstructured":"Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC: Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A\u200893: 7283\u20137288, 1996","DOI":"10.1073\/pnas.93.14.7283"},{"key":"2022031208093648400_R20","doi-asserted-by":"crossref","unstructured":"Couce M, Kane LA, O'Brien TD, Charlesworth J, Soeller W, McNeish J, Kreutter D, Roche P, Butler PC: Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and \u03b2-cell dysfunction. Diabetes\u200845: 1094\u20131101, 1996","DOI":"10.2337\/diab.45.8.1094"},{"key":"2022031208093648400_R21","doi-asserted-by":"crossref","unstructured":"Soeller WC, Janson J, Hart SE, Parker JC, Carty MD, Stevenson RW, Kreutter DK, Butler PC: Islet amyloid-associated diabetes in obese Avy\/a mice expressing human islet amyloid polypeptide. Diabetes\u200847: 743\u2013750, 1998","DOI":"10.2337\/diabetes.47.5.743"},{"key":"2022031208093648400_R22","doi-asserted-by":"crossref","unstructured":"Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE: Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic \u03b2-cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci U S A\u200893: 3492\u20133496, 1996","DOI":"10.1073\/pnas.93.8.3492"},{"key":"2022031208093648400_R23","doi-asserted-by":"crossref","unstructured":"Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC: Diabetes due to a progressive defect in \u03b2-cell mass in rats trangenic for human islet amyloid polypeptide (HIP rat). Diabetes\u200853: 1509\u20131516, 2004","DOI":"10.2337\/diabetes.53.6.1509"},{"key":"2022031208093648400_R24","doi-asserted-by":"crossref","unstructured":"Bonner-Weir S: Beta-cell turnover: its assessment and implications. Diabetes\u200850 (Suppl. 1): S20\u2013S24, 2001","DOI":"10.2337\/diabetes.50.2007.S20"},{"key":"2022031208093648400_R25","doi-asserted-by":"crossref","unstructured":"Konarkowska B, Aitken JF, Kistler J, Zhang S, Cooper GJS: The aggregation potential of human amylin determines its cytotoxicity towards islet \u03b2-cells. FEBS J\u2008273: 3614\u20133624, 2006","DOI":"10.1111\/j.1742-4658.2006.05367.x"},{"key":"2022031208093648400_R26","doi-asserted-by":"crossref","unstructured":"Zhang S, Liu J, Dragunow M, Cooper GJS: Fibrillogenic amylin evokes islet \u03b2-cell apoptosis through linked activation of a caspase cascade and JNK-1. J Biol Chem\u2008278: 52810\u201352819, 2003","DOI":"10.1074\/jbc.M308244200"},{"key":"2022031208093648400_R27","doi-asserted-by":"crossref","unstructured":"Haluzik M, Colombo C, Gavrilova O, Chua S, Wolf N, Chen M, Stannard B, Dietz KR, Le Roith D, Reitman ML: Genetic background (C57BL\/6J versus FVB\/N) strongly influences the severity of diabetes in insulin resistance in ob\/ob mice. Endocrinology\u2008145: 3258\u20133264, 2004","DOI":"10.1210\/en.2004-0219"},{"key":"2022031208093648400_R28","doi-asserted-by":"crossref","unstructured":"Porat Y, Kolusheva S, Jelinek R, Gazit E: The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochem\u200842: 10971\u201310977, 2003","DOI":"10.1021\/bi034889i"},{"key":"2022031208093648400_R29","doi-asserted-by":"crossref","unstructured":"Rumora L, Hadzija M, Barisic K, Maysinger D, Grubisic TZ: Amylin-induced cytotoxicity is associated with activation of caspase-3 and MAP kinases. Biol Chem\u2008383: 1751\u20131758, 2002","DOI":"10.1515\/BC.2002.196"},{"key":"2022031208093648400_R30","doi-asserted-by":"crossref","unstructured":"Zhang S, Liu H, Liu J, Tse CA, Dragunow M, Cooper GJS: Activation of activating transcription factor 2 by p38 MAP kinase during apoptosis induced by human amylin in cultured pancreatic \u03b2-cells. FEBS J\u2008273: 3779\u20133791, 2006","DOI":"10.1111\/j.1742-4658.2006.05386.x"},{"key":"2022031208093648400_R31","doi-asserted-by":"crossref","unstructured":"Zhang S, Liu J, Saafi EL, Cooper GJS: Induction of apoptosis by human amylin in RINm5F islet \u03b2-cells is associated with enhanced expression of p53 and p21. FEBS Lett\u2008455: 315\u2013320, 1999","DOI":"10.1016\/S0014-5793(99)00894-7"},{"key":"2022031208093648400_R32","doi-asserted-by":"crossref","unstructured":"Butler AE, Janson J, Soeller WC, Butler PC: Increased \u03b2-cell apoptosis prevents adaptive increase in \u03b2-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes\u200852: 2304\u20132314, 2003","DOI":"10.2337\/diabetes.52.9.2304"},{"key":"2022031208093648400_R33","doi-asserted-by":"crossref","unstructured":"Westermark GT, Gebre-Medhin S, Steiner DF, Westermark P: Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol Med\u20086: 998\u20131007, 2000","DOI":"10.1007\/BF03402051"},{"key":"2022031208093648400_R34","doi-asserted-by":"crossref","unstructured":"Wong HY, Ahren B, Lips CJM, Hoppener JWM, Sundler F: Postnatally disturbed pancreatic islet cell distribution in human islet amyloid polypeptide transgenic mice. Regul Peptides\u2008113: 89\u201394, 2003","DOI":"10.1016\/S0167-0115(02)00298-7"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/57\/10\/2737\/507176\/zdb01008002737.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/57\/10\/2737\/507176\/zdb01008002737.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:10:31Z","timestamp":1667405431000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/57\/10\/2737\/13352\/Spontaneous-Diabetes-in-Hemizygous-Human-Amylin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,1]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db06-1755","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,1]]}}}